Led US Oncology Forecasting and Analytics team after the acquisition of Seagen by Pfizer

Trusted advisor to leading cross-functional market insights generation and synthesis to enable decision-making for Finance, Manufacturing, and Commercial leaders.Expanded leadership role to include commercial analytics and forecasting, a team of 13 responsible for for assessing pipeline opportunities, commercial forecasting and goal setting, performance evaluation, and sales operations.

Supported new pediatric indication launch for ADCETRIS and expansion of urothelial indications for PADCEV. Provided commercial assessment to support to execute a $2bn cash out-licensing agreement for TUKYSA and LV and the in-licensing of disitamab vedotin

Built the first functional center of excellence for oncology forecasting at Seagen and managing team of 3 forecasters. Led US, global, in-line and pipeline forecasting for all oncology products and the Corporate Long Range Planning process. Provided commercial assessments to support business development and partnership decisions.Responsible for piloting and deploying new forecasting methodologies, e.g., Monte Carlo simulations, and the first regional forecasts to support the establishment of European affiliates. Led forecasting for initial product launches of TUKYSA, PADCEV, and TIVDAK in breast, urothelial, and cervical cancer.

Led forecasting, market research, and analytics for Adcetris, Supported the launch of frontline indications in Hodgkin's Lymphoma and Peripheral T-Cell Lymphoma.

Corporate strategy projects in commercializing new products and disruptive innovations in technology and biotechnology focused on:• Evaluating proposed investments, assessing product profiles against anticipated customer needs and competitive offerings• Positioning new products for market entry based on competitive landscape, development investments, and customers unmet need• Developing innovative pricing and commercial launch strategies to boost

• Investigated the impact of genetic variability on the human pathogenicity of fungi, authoring three original reports accepted for publication. • Trained and supervised undergraduate researchers to use microbiological techniques.

•Investigated the effects of interspecies variation in protein sequence on intracellular ligands and viral antagonists.•Reviewed research articles for scientific impact, originality, and importance for Molecular Biology and Evolution.

• Deployed to Iraq from 2004-2005 as Noncommissioned Officer in Charge of an 18 soldier detachment responsible for logistical support operations for a forward operating base of 5,000 soldiers and civilians.• Accelerated promotion from grade E-1 to E-6 in recognition of exceptional leadership.

• Highest ranking Noncommissioned Officer in charge of 18 soldiers deployed to Baghdad, Iraq.• Coordinated logistical and postal support for Forward Operating Base of 5,000 soldiers and civilians.• Received Army Commendation Medal and Army Achievement Medal for superior attention to detail and accomplishment of the mission while under fire.

• Responsible for Clinical Laboratory Improvement Amendments (CLIA) accounting and compliance. • Piloted new assays to detect clinically significant genetic mutations in disease associated genes.• Completed linkage analysis on multiple families to search for new genes associated with disease.